Atherogenic Index of Plasma tied to elevated risk of insulin resistance and Type 2 Diabetes

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-07-07 04:45 GMT   |   Update On 2023-07-07 09:30 GMT

China: A recent study published in Cardiovascular Diabetology has shown a link between the Atherogenic Index of Plasma (AIP) and the risk of insulin resistance (IR) and type 2 diabetes (T2D).The NHANES 2009-2018 analysis revealed that AIP showed a J-shaped association with T2D and an inverse L-shaped association with insulin resistance, implying that AIP be reduced to a certain level to...

Login or Register to read the full article

China: A recent study published in Cardiovascular Diabetology has shown a link between the Atherogenic Index of Plasma (AIP) and the risk of insulin resistance (IR) and type 2 diabetes (T2D).

The NHANES 2009-2018 analysis revealed that AIP showed a J-shaped association with T2D and an inverse L-shaped association with insulin resistance, implying that AIP be reduced to a certain level to prevent type 2 diabetes and insulin resistance.

"People with AIP >− 0.47 and < 0.45 were at significantly greater risks of T2D and IR, representing an L-shaped and J-shaped link between AIP & IR and AIP & T2D, respectively," the researchers reported. "These findings indicate that AIP can be used as a monitoring indicator of IR and T2D."

Several studies have suggested epidemiological risk factors for IR-related metabolic disease, but data is still inadequate to explore the non-linear association of AIP with insulin resistance. Therefore, Lingling Chen, Department of Traditional Chinese Medicine, Shenzhen People's Hospital, Shenzhen, China, and colleagues aimed to elucidate the non-linear relationship between AIP and IR and type 2 diabetes in a cross-sectional study.

The study was conducted in the NHANES (National Health and Nutrition Survey) from 2009 to 2018, including 9,245 participants. The AIP was calculated as log10 (triglycerides/high-density lipoprotein cholesterol).

The outcome variables were type 2 diabetes and insulin resistance, defined by the 2013 ADA (American Diabetes Association) guidelines. The relationship of AIP with IR and T2D was determined using weighted multivariate logistic regression, weighted multivariate linear regression, generalized additive model, subgroup analysis, two-part logistic regression, and a smooth fitting curve.

The authors reported the following findings:

· After adjustment for age, race, gender, smoking status, education level, alcohol consumption, body mass index, vigorous/moderate physical activity, waist circumference and hypertension, AIP was found to be positively associated with fasting blood glucose (β = 0.08), glycosylated haemoglobin (β = 0.04), fasting serum insulin (β = 4.26), and homeostasis model assessment of insulin resistance (β = 0.22).

· Further studies found that AIP was associated with an increased risk of IR (OR = 1.29) and T2D (OR = 1.18).

· The positive association between AIP and IR or T2D was more significant in females than males.

· A non-linear and inverse L-shaped association was found between AIP and IR, while a J-shaped association was found between AIP and T2D.

· In patients with − 0.47 < AIP < 0.45, increased AIP was significantly associated with increased risk of IR and T2D.

"These findings indicate that reducing AIP levels within a certain range may positively affect the prevention and treatment of IR and T2D," the authors concluded. "However, there is a need for more investigations to confirm the causal relationship and underlying mechanisms."

Reference:

Yin, B., Wu, Z., Xia, Y. et al. Non-linear association of atherogenic index of plasma with insulin resistance and type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol 22, 157 (2023). https://doi.org/10.1186/s12933-023-01886-5


Tags:    
Article Source : Cardiovascular Diabetology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News